Carolina L Haass-Koffler

List of Publications by Year
in descending order

43 papers	876 citations	623734 14 h-index	501196 28 g-index
45 all docs	45 docs citations	45 times ranked	1157 citing authors

#	Article	IF	Citations
1	Opioid use and stigma: The role of gender, language and precipitating events. Drug and Alcohol Dependence, 2018, 185, 339-346.	3.2	120
2	Mifepristone in the Central Nucleus of the Amygdala Reduces Yohimbine Stress-Induced Reinstatement of Ethanol-Seeking. Neuropsychopharmacology, 2012, 37, 906-918.	5.4	89
3	Pharmacological Approaches to Reducing Craving in Patients with Alcohol Use Disorders. CNS Drugs, 2014, 28, 343-360.	5.9	65
4	Role of the Î±₁blocker doxazosin in alcoholism: a proof-of-concept randomized controlled trial. Addiction Biology, 2016, 21, 904-914.	2.6	58
5	Noradrenergic targets for the treatment of alcohol use disorder. Psychopharmacology, 2018, 235, 1625-1634.	3.1	51
6	Stress and addiction: contribution of the corticotropin releasing factor (CRF) system in neuroplasticity. Frontiers in Molecular Neuroscience, 2012, 5, 91.	2.9	48
7	Pharmacotherapy for alcoholic patients with alcoholic liver disease. American Journal of Health-System Pharmacy, 2014, 71, 1265-1276.	1.0	42
8	Higher pretreatment blood pressure is associated with greater alcohol drinking reduction in alcohol-dependent individuals treated with doxazosin. Drug and Alcohol Dependence, 2017, 177, 23-28.	3.2	38
9	The Î±5 Subunit Regulates the Expression and Function of Î±4*-Containing Neuronal Nicotinic Acetylcholine Receptors in the Ventral-Tegmental Area. PLoS ONE, 2013, 8, e68300.	2.5	36
10	Ondansetron Reduces Naturalistic Drinking in Nontreatment-Seeking Alcohol-Dependent Individuals with the LL 5â€²-HTTLPR Genotype: A Laboratory Study. Alcoholism: Clinical and Experimental Research, 2014, 38, 1567-1574.	2.4	31
11	A Phase I randomized clinical trial testing the safety, tolerability and preliminary pharmacokinetics of the mGluR5 negative allosteric modulator GET 73 following single and repeated doses in healthy volunteers. European Journal of Pharmaceutical Sciences, 2017, 109, 78-85.	4.0	29
12	Comparing and Combining Topiramate and Aripiprazole on Alcohol-Related Outcomes in a Human Laboratory Study. Alcohol and Alcoholism, 2018, 53, 268-276.	1.6	24
13	Ondansetron and sertraline may interact with 5-HTTLPR and DRD4 polymorphisms to reduce drinking in non-treatment seeking alcohol-dependent women: Exploratory findings. Alcohol, 2014, 48, 515-522.	1.7	19
14	Relationship Between the Thyroid Axis and Alcohol Craving. Alcohol and Alcoholism, 2015, 50, 24-29.	1.6	19
15	The Amygdala Noradrenergic System Is Compromised With Alcohol Use Disorder. Biological Psychiatry, 2022, 91, 1008-1018.	1.3	18
16	An Analytical Tool that Quantifies Cellular Morphology Changes from Three-dimensional Fluorescence Images. Journal of Visualized Experiments, 2012, , e4233.	0.3	13
17	Dataset for Phase I randomized clinical trial for safety and tolerability of GET 73 in single and repeated ascending doses including preliminary pharmacokinetic parameters. Data in Brief, 2017, 15, 407-413.	1.0	13
18	Association of Substance Use With Behavioral Adherence to Centers for Disease Control and Prevention Guidelines for COVID-19 Mitigation: Cross-sectional Web-Based Survey. JMIR Public Health and Surveillance, 2021, 7, e29319.	2.6	13

#	Article	IF	Citations
19	Effects of Idazoxan on Alcohol Pharmacokinetics and Intoxication: A Preliminary Human Laboratory Study. Alcoholism: Clinical and Experimental Research, 2015, 39, 594-602.	2.4	12
20	Serum Insulin Levels Are Reduced by Intravenous Ghrelin Administration but Do Not Correlate with Alcohol Craving in Alcohol-Dependent Individuals. International Journal of Neuropsychopharmacology, 2016, 19, pyw048.	2.1	11
21	Intravenous administration of ghrelin increases serum cortisol and aldosterone concentrations in heavy-drinking alcohol-dependent individuals: Results from a double-blind, placebo-controlled human laboratory study. Neuropharmacology, 2019, 158, 107711.	4.1	11
22	Differences in Sociodemographic and Alcoholâ€Related Clinical Characteristics Between Treatment Seekers and Nontreatment Seekers and Their Role in Predicting Outcomes in the COMBINE Study for Alcohol Use Disorder. Alcoholism: Clinical and Experimental Research, 2020, 44, 2097-2108.	2.4	11
23	Alcohol Tolerance in Human Laboratory Studies for Development of Medications to treat Alcohol Use Disorder. Alcohol and Alcoholism, 2020, 55, 129-135.	1.6	11
24	Neuroendocrine Response to Exogenous Ghrelin Administration, Combined With Alcohol, in Heavy-Drinking Individuals: Findings From a Randomized, Double-Blind, Placebo-Controlled Human Laboratory Study. International Journal of Neuropsychopharmacology, 2021, 24, 464-476.	2.1	11
25	Altering ethanol pharmacokinetics to treat alcohol use disorder: Can you teach an old dog new tricks?. Journal of Psychopharmacology, 2017, 31, 812-818.	4.0	10
26	Administration of the metabotropic glutamate receptor subtype 5 allosteric modulator GET 73 with alcohol: A translational study in rats and humans. Journal of Psychopharmacology, 2018, 32, 163-173.	4.0	10
27	Bacchus by Caravaggio as the Visual Diagnosis of Alcohol Use Disorder from the Fifth Edition of the Diagnostic and Statistical Manual of Mental Disorders (DSM-5). Frontiers in Psychiatry, 2013, 4, 86.	2.6	9
28	Opioid Craving in Human Laboratory Settings: a Review of the Challenges and Limitations. Neurotherapeutics, 2020, 17, 100-104.	4.4	9
29	Probenecid Reduces Alcohol Drinking in Rodents. Is Pannexin1 a Novel Therapeutic Target for Alcohol Use Disorder?. Alcohol and Alcoholism, 2019, 54, 497-502.	1.6	8
30	The corticotropin releasing factor binding protein: A strange case of Dr. Jekyll and Mr. Hyde in the stress system?. Alcohol, 2018, 72, 3-8.	1.7	7
31	Corticotropin Releasing Factor Binding Protein as a Novel Target to Restore Brain Homeostasis: Lessons Learned From Alcohol Use Disorder Research. Frontiers in Behavioral Neuroscience, 2021, 15, 786855.	2.0	7
32	Brief Report: Relationship Between Cotinine Levels and Peripheral Endogenous Concentrations of Oxytocin, Î²â€Endorphin, and Orexin in Individuals With Both Alcohol and Nicotine Use Disorders. American Journal on Addictions, 2021, 30, 88-91.	1.4	5
33	An inpatient human laboratory study assessing the safety and tolerability, pharmacokinetics, and biobehavioral effect of GET 73 when co-administered with alcohol in individuals with alcohol use disorder. Psychopharmacology, 2021, , 1.	3.1	4
34	Yohimbine as a pharmacological probe for alcohol research: a systematic review of rodent and human studies. Neuropsychopharmacology, 2022, 47, 2111-2122.	5.4	4
35	New Microglial Mechanisms Revealed in Alcohol Use Disorder: How Does That Translate?. Biological Psychiatry, 2020, 88, 893-895.	1.3	3
36	A Combined Alcohol and Smoking Cue-Reactivity Paradigm in People Who Drink Heavily and Smoke Cigarettes: Preliminary Findings. Alcohol and Alcoholism, 2021, 56, 47-56.	1.6	2

#	Article	IF	Citations
37	Translational dynamics of alcohol tolerance of preclinical models and human laboratory studies.. Experimental and Clinical Psychopharmacology, 2020, 28, 417-425.	1.8	2
38	Translational Research in the Neurobiological Mechanisms of Alcohol and Substance Use Disorders. Neurotherapeutics, 2020, 17, 1-3.	4.4	1
39	Randomized controlled trials for alcohol use disorder during the COVID-19 pandemic. Alcohol, 2021, 92, 21-24.	1.7	1
40	Alcohol-related changes in behaviors and characteristics from the baseline to the randomization session for treatment and non-treatment seeking participants with alcohol use disorder. American Journal of Drug and Alcohol Abuse, 2021, , 1-9.	2.1	1
41	A chimeric approach to evaluate the role of corticotropin releasing factor in alcohol use disorder. Alcohol, 2017, 60, 222-223.	1.7	0
42	S08-2TOWARDS PERSONALIZED TREATMENTS FOR ALCOHOL USE DISORDER: A FOCUS ON ALPHA-1 BLOCKADE. Alcohol and Alcoholism, 2017, 52, i4-i30.	1.6	0
43	Protein Tyrosine Phosphatase Î²ÍÎ¶ and Alcohol Use Disorder: A Commentary. Alcoholism: Clinical and Experimental Research, 2020, 44, 1189-1191.	2.4	0